Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) of up to 40 kg/m2~* Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior~* Diagnosis of PBH~* At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia~Exclusion Criteria:~* Other cause of endogenous hyperinsulinism other than PBH~* Metabolic or bariatric surgical procedure other than RYGB~* History of non-RYGB upper GI surgery~* Use of agents that may interfere with glucose metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): patients will receive two dose regimens of exendin 9-39 and one placebo
- Treatment Group 2 (Type: EXPERIMENTAL): patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).